Suppr超能文献

静脉注射考尼伐坦治疗等容性和高容性低钠血症的疗效和安全性评估。

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

作者信息

Zeltser David, Rosansky Steven, van Rensburg Hannes, Verbalis Joseph G, Smith Neila

机构信息

Department of Internal Medicine D, Sourasky Medical Center, Tel Aviv, Israel.

出版信息

Am J Nephrol. 2007;27(5):447-57. doi: 10.1159/000106456. Epub 2007 Jul 26.

Abstract

BACKGROUND

Most cases of hyponatremia--serum sodium concentration ([Na+]) < 135 mEq/l (< 135 mM)--are associated with an elevated plasma arginine vasopressin level. This study investigated the efficacy and tolerability of intravenous conivaptan (YM087), a vasopressin V1A/V2-receptor antagonist, in treating euvolemic and hypervolemic hyponatremia.

METHODS

Eighty-four hospitalized patients with euvolemic or hypervolemic hyponatremia (serum [Na+] 115 to < 130 mEq/l) were randomly assigned to receive intravenous placebo or conivaptan administered as a 30-min, 20-mg loading dose followed by a 96-hour infusion of either 40 or 80 mg/day. The primary efficacy measure was change in serum [Na+], measured by the baseline-adjusted area under the [Na+]-time curve. The secondary measures included time from first dose to a confirmed > or = 4 mEq/l serum [Na+] increase, total time patients had serum [Na+] > or = 4 mEq/l higher than baseline, change in serum [Na+] from baseline to the end of treatment, and number of patients with a confirmed > or = 6 mEq/l increase in serum [Na+] or normal [Na+] (> or = 135 mEq/l).

RESULTS

Both conivaptan doses increased area under the [Na+]-time curve during the 4-day treatment (p < 0.0001 vs. placebo). From baseline to the end of treatment, the least-squares mean +/- standard error serum [Na+] increase associated with placebo was 0.8 +/- 0.8 mEq/l; with conivaptan 40 mg/day, 6.3 +/- 0.7 mEq/l; and with conivaptan 80 mg/day, 9.4 +/- 0.8 mEq/l. Conivaptan significantly improved all secondary efficacy measures (p < 0.001 vs. placebo, both doses). Conivaptan was generally well tolerated, although infusion-site reactions led to the withdrawal of 1 (3%) and 4 (15%) of patients given conivaptan 40 and 80 mg/day, respectively.

CONCLUSION

Among patients with euvolemic or hypervolemic hyponatremia, 4-day intravenous infusion of conivaptan 40 mg/day significantly increased serum [Na+] and was well tolerated.

摘要

背景

大多数低钠血症病例——血清钠浓度([Na⁺])<135 mEq/L(<135 mM)——与血浆精氨酸加压素水平升高有关。本研究调查了血管加压素V1A/V2受体拮抗剂静脉注射考尼伐坦(YM087)治疗等容性和高容性低钠血症的疗效和耐受性。

方法

84例住院的等容性或高容性低钠血症患者(血清[Na⁺]为115至<130 mEq/L)被随机分配接受静脉注射安慰剂或考尼伐坦,先给予30分钟20毫克的负荷剂量,然后以40或80毫克/天的剂量进行96小时输注。主要疗效指标是血清[Na⁺]的变化,通过[Na⁺]-时间曲线下经基线调整的面积来测量。次要指标包括从首次给药到确认血清[Na⁺]升高≥4 mEq/L的时间、患者血清[Na⁺]比基线高≥4 mEq/L的总时间、从基线到治疗结束时血清[Na⁺]的变化,以及确认血清[Na⁺]升高≥6 mEq/L或血清[Na⁺]正常(≥135 mEq/L)的患者数量。

结果

在4天的治疗期间,考尼伐坦的两个剂量均增加了[Na⁺]-时间曲线下的面积(与安慰剂相比,p<0.0001)。从基线到治疗结束,与安慰剂相关的血清[Na⁺]升高的最小二乘均值±标准误为0.8±0.8 mEq/L;考尼伐坦40毫克/天组为6.3±0.7 mEq/L;考尼伐坦80毫克/天组为9.4±0.8 mEq/L。考尼伐坦显著改善了所有次要疗效指标(与安慰剂相比,两个剂量组p均<0.001)。考尼伐坦总体耐受性良好,尽管输注部位反应导致分别有1例(3%)接受40毫克/天考尼伐坦治疗的患者和4例(15%)接受80毫克/天考尼伐坦治疗的患者退出研究。

结论

在等容性或高容性低钠血症患者中,4天静脉输注40毫克/天的考尼伐坦可显著提高血清[Na⁺]水平,且耐受性良好。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验